- Home
- RMTI vs NRXP Comparison
RMTI vs NRXP Comparison
Compare RMTI & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- NRXP
- Stock Information
- Founded
- RMTI 1994
- NRXP 2015
- Country
- RMTI United States
- NRXP United States
- Employees
- RMTI N/A
- NRXP N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- RMTI Health Care
- NRXP Health Care
- Exchange
- RMTI Nasdaq
- NRXP Nasdaq
- Market Cap
- RMTI 33.0M
- NRXP 32.6M
- IPO Year
- RMTI 1998
- NRXP N/A
- Fundamental
- Price
- RMTI $0.91
- NRXP $3.29
- Analyst Decision
- RMTI Strong Buy
- NRXP Strong Buy
- Analyst Count
- RMTI 2
- NRXP 4
- Target Price
- RMTI $4.00
- NRXP $28.50
- AVG Volume (30 Days)
- RMTI 163.6K
- NRXP 288.4K
- Earning Date
- RMTI 08-07-2025
- NRXP 08-13-2025
- Dividend Yield
- RMTI N/A
- NRXP N/A
- EPS Growth
- RMTI N/A
- NRXP N/A
- EPS
- RMTI N/A
- NRXP N/A
- Revenue
- RMTI $97,727,000.00
- NRXP N/A
- Revenue This Year
- RMTI N/A
- NRXP N/A
- Revenue Next Year
- RMTI $11.16
- NRXP N/A
- P/E Ratio
- RMTI N/A
- NRXP N/A
- Revenue Growth
- RMTI 12.82
- NRXP N/A
- 52 Week Low
- RMTI $0.86
- NRXP $1.10
- 52 Week High
- RMTI $5.15
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- RMTI 39.80
- NRXP 60.87
- Support Level
- RMTI $0.91
- NRXP $3.14
- Resistance Level
- RMTI $1.00
- NRXP $3.61
- Average True Range (ATR)
- RMTI 0.05
- NRXP 0.26
- MACD
- RMTI -0.00
- NRXP -0.02
- Stochastic Oscillator
- RMTI 11.71
- NRXP 53.17
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.